Regenxbio
RGNX· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +86.3% in FY2025
Curran Simpson is the CEO of Regenxbio and was paid $4.2M in FY2025 (Dec), down 12%.
Pay$100 in the stock at the end of FY20 → $32
Executives3
See all- 1Curran SimpsonPresident and Chief Executive OfficerFY2025
- 2Patrick J. ChristmasEVP, Chief Strategy and Legal OfficerFY2025
- 3Stephen Pakola, M.D.EVP, Chief Medical OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allRegenxbio paid its 3 named executives $8.0M in total in FY2025 (Dec). CEO Curran Simpson was paid $4.2M of that.
| Name | |||
|---|---|---|---|
| Curran SimpsonPresident and Chief Executive Officer | |||
| Patrick J. ChristmasEVP, Chief Strategy and Legal Officer | Not disclosed | ||
| Stephen Pakola, M.D.EVP, Chief Medical Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Regenxbio. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 14, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 8, 2025 | FY2024 |
| Annual report | 10-K | Mar 13, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 4, 2024 | FY2023 |
| Annual report | 10-K | Feb 27, 2024 | FY2023 |
